SEC Comment Letter 0000000000-24-013056 to PMV Pharmaceuticals, Inc. (PMVP) (CIK 0001699382) (PMVP)
PMV Pharmaceuticals, Inc. (PMVP) (CIK 0001699382)
Date: Nov. 25, 2024 · CIK: 0001699382 · Accession: 0000000000-24-013056
AI Filing Summary & Sentiment
File numbers found in text: 333-283349
Letter
November 25, 2024 David Mack, Ph.D. Chief Executive Officer PMV Pharmaceuticals, Inc. 400 Alexander Park Drive, Suite 301 Princeton, NJ 08540 Re:PMV Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed November 20, 2024 File No. 333-283349 Dear David Mack Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Megan Baier, Esq.
Show Raw Text
November 25, 2024
David Mack, Ph.D.
Chief Executive Officer
PMV Pharmaceuticals, Inc.
400 Alexander Park Drive, Suite 301
Princeton, NJ 08540
Re:PMV Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed November 20, 2024
File No. 333-283349
Dear David Mack Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Megan Baier, Esq.